Trial
NCT05629364
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Kiora Pharmaceuticals, Inc.
Collaborators
—
Condition
Dry Eye Disease
Intervention
KIO-101
Why stopped
Study halted prematurely but potentially will resume
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-10